Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 18/20 | 1.00 |
| ▸ | HTR2A | P28223 | 17/20 | 1.00 |
| ▸ | HTR2B | P41595 | 13/20 | 1.00 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6603614 | 1.00 | HTR2C (1.00) | HTR2CHTR2AHTR2BTLR7CYP3A4 | |
| SCHEMBL6605040 | 1.00 | HTR2C (1.00) | HTR2CHTR2AHTR2BTLR7CYP3A4 | |
| Hydrochloric Acid SCHEMBL6604400 | 0.99 | HTR2C (0.97) | HTR2CHTR2AHTR2BTLR7CYP3A4 | |
| Hydrochloric Acid SCHEMBL6607981 | 0.99 | HTR2C (0.97) | HTR2CHTR2AHTR2BTLR7CYP3A4 | |
| Fumaric Acid SCHEMBL6602921 | 0.90 | HTR2A (0.80) | HTR2CHTR2AHTR2BTLR7 | |
| Fumaric Acid SCHEMBL6602847 | 0.90 | HTR2A (0.80) | HTR2CHTR2AHTR2BTLR7 | |
| Fumaric Acid SCHEMBL6602929 | 0.90 | HTR2A (0.80) | HTR2CHTR2AHTR2BTLR7 | |
| Fumaric Acid SCHEMBL6602840 | 0.90 | HTR2A (0.80) | HTR2CHTR2AHTR2BTLR7 | |
| SCHEMBL4826871 | 0.86 | HTR2A (0.76) | HTR2CHTR2AHTR2BTLR7CYP3A4 | |
| SCHEMBL6602404 | 0.86 | HTR2A (0.76) | HTR2CHTR2AHTR2BTLR7CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170239237-A1 | PYRROLOQUINOLINE DERIVATIVES AS 5-HT6 ANTAGONISTS, PREPARATION METHOD AND USE THEREOF | UNIVERSITE DE MONTPELLIER (FR) | 2017-08-24 | — | — | US | disclosed |
| WO-2015012704-A1 | PYRROLOQUINOLINE DERIVATIVES AS 5-HT6 ANTAGONISTS, PREPARATION METHOD AND USE THEREOF | Uniwersytet Jagielloński (PL) | 2015-01-29 | — | — | WO | disclosed |
| EP-1109809-B1 | PYRROLOQUINOLINES FOR TREATMENT OF OBESITY | CEREBRUS PHARM LTD (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-6365598-B1 | FOR THERAPY AND PROPHYLAXIS OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM; DAMAGE TO THE CENTRAL NERVOUS SYSTEM; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; DIABETES INSIPIDUS; AND SLEEP APNEA | VERNALIS RESEARCH LIMITED (GB) | 2002-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239237-A1 | PYRROLOQUINOLINE DERIVATIVES AS 5-HT6 ANTAGONISTS, PREPARATION METHOD AND USE THEREOF | HTR6, HTR2C, HTR3B | HTR2C 2/4885HTR2A 6/4885HTR2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.